Welch Group LLC Takes Position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT)
Welch Group LLC Takes Position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT)
Welch Group LLC purchased a new stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 58,700 shares of the company's stock, valued at approximately $101,000.
根據最近向證券交易委員會提交的 13F 表格,韋爾奇集團有限責任公司在第三季度購買了阿拉諾斯治療有限公司(NASDAQ:TCRT-獲得評級)的新股份。該公司購買了該公司股票 58,700 股,價值約為 101,000 美元。
Other hedge funds have also recently made changes to their positions in the company. Sugarloaf Wealth Management LLC acquired a new stake in shares of Alaunos Therapeutics during the third quarter valued at about $136,000. Commerce Bank bought a new position in shares of Alaunos Therapeutics during the second quarter worth about $569,000. CIBC Private Wealth Group LLC bought a new position in shares of Alaunos Therapeutics during the second quarter worth about $51,000. Kettle Hill Capital Management LLC bought a new position in shares of Alaunos Therapeutics during the second quarter worth about $427,000. Finally, Gamble Jones Investment Counsel bought a new position in shares of Alaunos Therapeutics during the second quarter worth about $76,000. 33.88% of the stock is owned by institutional investors and hedge funds.
其他對沖基金最近也對其在公司的頭寸進行了更改。糖麵包山財富管理有限責任公司在第三季度收購了阿勞諾斯治療藥物股份的新股份,價值約為 136,000 美元。商業銀行在第二季度期間購買了阿拉諾斯治療學股份的新位置,價值約為 $569,000。CIBC 私人財富集團有限責任公司在第二季度購買了阿拉諾斯治療股份的新位置,價值約為 $51,000。水壺山資本管理有限責任公司在第二季度購買了阿拉烏諾斯治療的股份新位置,價值約 $427,000.最後,賭博瓊斯投資顧問在第二季度購買了阿拉諾斯治療股份的新頭寸,價值約為 76,000 美元。33.88% 的股票由機構投資者和對沖基金擁有。
Wall Street Analyst Weigh In
華爾街分析師稱重
Separately, Wells Fargo & Company restated an "overweight" rating and set a $3.00 price objective on shares of Alaunos Therapeutics in a research report on Tuesday, October 4th.
另外,富國銀行公司在 10 月 4 日(星期二)的一份研究報告中重申了「超重」評級,並對 Alaunos 治療的股票設定了 3.00 美元的價格目標。
Alaunos Therapeutics Price Performance
阿拉努斯治療價格表現
Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The business had revenue of $2.91 million during the quarter. As a group, sell-side analysts anticipate that Alaunos Therapeutics, Inc. will post -0.16 EPS for the current year.
阿勞諾斯治療(NASDAQ:TCRT-獲得評級)上次發布了其收益業績,週一,11 月 14 日。該公司報告了本季度每股盈利(0.04 美元),頂部分析師的共識估計為 0.08 美元(0.12 美元)。該業務在本季度的收入為 2.91 萬美元。作為一個集團,賣方分析師預計,阿拉努斯治療, Inc. 將在本年度發布 -0.16 每股盈利。
Insiders Place Their Bets
內部人士下注
In other Alaunos Therapeutics news, Director Robert W. Postma bought 750,000 shares of the stock in a transaction on Tuesday, November 29th. The stock was acquired at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the completion of the acquisition, the director now owns 5,000,000 shares in the company, valued at approximately $3,250,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.90% of the stock is currently owned by corporate insiders.
在其他阿勞諾斯治療新聞中,導演羅伯特 ·W· 波斯特馬在 11 月 29 日(週二)的一次交易中購買了該股票的 75 萬股。該股票以每股 0.65 美元的平均成本收購,總交易額為 487,500.00 美元。收購完成後,董事現在擁有該公司 5,000,000 股股份,價值約 3,250,000 美元。該收購已在向證券交易委員會提交的文件中披露,該文件可通過以下方式訪問 證券交易所網站。4.90% 的股票目前由企業內部人士擁有。
About Alaunos Therapeutics
關於阿朗諾斯治療
(Get Rating)
(取得評分)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
Alaunos 治療, Inc 是一家以臨床階段腫瘤學為中心的細胞治療公司,開發採用 TCR 工程 T 細胞療法。該公司開發了 TCR 圖書館,該圖書館在其 TCR 庫中針對非小細胞肺,結直腸癌,子宮內膜,胰腺癌,卵巢癌和膽管癌反應十 TCR 進行 I/II 期臨床試驗;HunTR 是一種人類腫瘤抗原 T 細胞受體受體平台;以及 mBIL15 治療腫瘤。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- 獲取有關阿拉胡諾斯治療(TCRT)的研究報告的免費副本
- 如果馬斯克從推特下台,特斯拉會分享反彈嗎?
- 5 年要關注的 2023 年股票下跌但未熄滅
- 耐嚼可以在 2023 年獲得雙位數的收益嗎?
- 儘管面臨面臨挑戰,但 Eli Lilly 預計持續增長
- 馬德里加爾藥品股票在一天內上漲 200%,這就是為什麼
Want to see what other hedge funds are holding TCRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating).
想看看還有哪些對沖基金持有 TCRT? 訪問 Holdingschannel.com 以獲取有關阿拉諾斯治療公司(NASDAQ:TCRT-獲得評分)的最新 13 樓文件和內幕交易。
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收阿拉努斯治療的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Alaunos 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。